Levicept

With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability. Levicept Ltd is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. We are progressing LEVI-04 to phase I clinical trials to test its efficacy and safety in patients with osteoarthritis.
Type
Private
HQ
Sandwich, GB
Founded
2012
Levicept was founded in 2012 and is headquartered in Sandwich, GB

Key People at Levicept

Simon Westbrook

Simon Westbrook

CEO

Levicept Office Locations

Levicept has an office in Sandwich
Sandwich, GB (HQ)
Ramsgate Rd

Levicept Data and Metrics

Summary Metrics

Founding Date

2012

Total Funding

$16.1 m

Latest funding size

$3.9 m

Time since last funding

almost 3 years

Investors

Levicept's latest funding round in October 2014 was reported to be $3.9 m. In total, Levicept has raised $16.1 m

Levicept Financial Metrics

GBP

Net income (FY, 2015)

(3.7 m)

Cash (30-Sep-2016)

2.4 m
GBPFY, 2014FY, 2015

Cost of goods sold

256.7 k3.3 m

Pre tax profit

(427.8 k)(3.7 m)

Net Income

(427.8 k)(3.7 m)
GBPFY, 2014FY, 2015FY, 2016

Cash

3.9 m3.5 m2.4 m

Accounts Receivable

256.2 k414.4 k

Current Assets

4 m3.7 m2.8 m

PP&E

3.9 k7.3 k32 k

Total Assets

4 m3.8 m2.8 m

Accounts Payable

117.3 k115.8 k191.8 k

Current Liabilities

144.9 k144.7 k191.8 k

Total Liabilities

1.1 m1.7 m2.5 m

Retained Earnings

(427.8 k)(3.7 m)

Total Equity

2.9 m2.1 m332 k

Financial Leverage

1.4 x1.8 x8.5 x
Y, 2016

Financial Leverage

8.5 x

Levicept Online and Social Media Presence

Levicept Company Life and Culture

You may also be interested in